Weight Management

Overview

Weight management is one of the most active areas in contemporary pharmacology. In the last five years, medicines that mimic gut hormones — the incretin agonists — have produced weight reductions in randomised trials that, until recently, only bariatric surgery could reliably deliver. The field is moving quickly, and the gap between what is in labels, what is in phase-3 trials, and what is being discussed online is wide.

This page summarises what current research says about the peptides most often discussed for weight management: what has been approved, what is in development, how the evidence is graded, and what safety considerations recur across the class.

Current research

The current standard of care for chronic weight management with a medicine is a once-weekly GLP-1 or dual incretin agonist. Semaglutide (Wegovy) was the first of the modern class to receive an obesity indication. Tirzepatide (Zepbound), a dual GIP/GLP-1 agonist, was approved shortly after and outperformed semaglutide on head-to-head endpoints in type 2 diabetes trials.

In development, the leading candidate is retatrutide — a triple agonist targeting GLP-1, GIP, and glucagon receptors — which in phase-2 data has shown mean body-weight reductions in the low twenties percent at 48 weeks. Its phase-3 program (TRIUMPH) is ongoing, and it is not available outside those trials.

A second axis of research is on maintenance: what happens when a person stops. SURMOUNT-4 tested this directly for tirzepatide — after an initial weight-loss phase, participants randomised to continue the medicine kept losing or maintained; those switched to placebo regained a substantial fraction. Long-term chronic use appears to be the model that current evidence supports.

• GLP-1 monotherapy

  Semaglutide 2.4 mg (Wegovy) — mean weight reduction ~15% at 68 weeks in STEP-1. First modern-class approval for obesity (US 2021, EU 2022).

• Dual incretin agonism

  Tirzepatide (Zepbound / Mounjaro) — mean weight reduction ~20.9% at 72 weeks at the highest dose in SURMOUNT-1. Approved US 2023, EU 2023.

• Triple agonism (investigational)

  Retatrutide — mean weight reduction ~24% at 48 weeks at the highest dose in phase-2. Phase-3 TRIUMPH program ongoing. Not currently approved anywhere.

• Older mechanisms (limited role)

  AOD-9604 (hGH fragment) targets lipolysis directly but produces small effect sizes vs. incretin therapy. Historically clinically deprioritised in favour of newer classes.

Compounds being investigated

The following compounds in the Healthy Mango library have been studied specifically for weight management. Each links to a full compound page with mechanism, evidence, dosing reported in research, safety, and references.

Other compounds discussed in general weight-loss forums (older GH-axis peptides, thyroid agonists, sympathomimetics) are outside the scope of what current evidence supports for durable weight reduction and are not covered under this topic.

• Dual incretin receptor agonist

  Tirzepatide

  A single molecule that activates GIP and GLP-1 receptors across the pancreas, gut, and brain. Tirzepatide is approved by the FDA and EMA for specified indications involving type 2 diabetes and chronic weight management, under distinct brands and regulatory labeling.

  Strong Human Evidence

• GLP-1 receptor agonist

  Semaglutide

  A once-weekly (subcutaneous) or once-daily (oral) GLP-1 receptor agonist approved by the FDA and EMA under distinct brand names for type 2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy), and cardiovascular risk reduction in specified populations. It signals through a single incretin receptor, without direct GIP or glucagon receptor activity.

  Strong Human Evidence

• Triple incretin / glucagon receptor agonist

  Retatrutide

  An investigational once-weekly molecule that activates three receptors at once — GIP, GLP-1, and glucagon. In Phase 3 clinical development (Eli Lilly's TRIUMPH program) for obesity and type 2 diabetes. Not approved by any regulator; no approved commercial formulation; no standardized public reconstitution instructions.

  Moderate Human Evidence

Evidence summary

Evidence for the incretin agonists as a class is strong in the sense of level A: multiple large, well-designed randomised controlled trials in humans, with regulatory approval, and with active post-marketing safety surveillance. Effect sizes are consistent across trials.

Evidence for the older mechanisms (hGH fragments, non-incretin appetite modulators, thyroid analogues) is substantially weaker. Preclinical and early human data exist, but head-to-head performance vs. an approved incretin agonist would not favour them.

• Once-weekly subcutaneous injection is the dominant route across the modern class.
• Effect on weight is contingent on continued use in every well-controlled trial to date.
• Head-to-head trials favour dual incretin agonism (tirzepatide) over selective GLP-1 monotherapy (semaglutide) for both weight and glycaemic endpoints.
• Cardiovascular outcome trials are ongoing; select-CVD data for semaglutide (SELECT) show cardiovascular benefit in obesity without diabetes.

Safety considerations

Safety signals recur across the incretin class and are the leading reason participants discontinue treatment in trials.

• Dose-dependent gastrointestinal effects (nausea, vomiting, diarrhoea) — most intense during titration; usually transient.
• Cholelithiasis (gallstones) — increased incidence vs. placebo across large trials.
• Acute pancreatitis — rare but described. Investigate severe abdominal pain radiating to the back promptly.
• Hypoglycaemia — primarily in the presence of insulin or sulphonylureas.
• Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or MEN 2, based on rodent studies; human relevance is unclear but the label is explicit.
• Not recommended in pregnancy per current labelling. Long-term data on lactation are limited.
• Absorption of other oral medications may be delayed by gastroparesis — relevant for oral contraceptives and time-sensitive drugs.